Table 1_Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma.docx by Dewan Zhao (21547445)

“…High baseline high-density lipoprotein cholesterol (HDL-C) was associated with reduced progression risk (HR = 0.27, 95% CI: 0.10-0.78), while high baseline low-density lipoprotein cholesterol (LDL-C) was linked to decreased CR rate (OR = 0.65, 95% CI: 0.44-0.97) and increased progression risk (HR = 1.78, 95% CI: 1.14-2.79). …”

Table4_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”

Table3_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”

Table6_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”

Table2_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”

Table5_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

“…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”

<i>β</i>^<i>P</i> for real-world twitter datasets. by Xi Chen (35903)

Subjects:

Expression of <i>pax7</i> genes increases during white muscle regeneration in trout. by Cécile Rallière (86527)

Based on three WS models with different rewiring probabilities (<i>n</i> = 100, <i>K</i> = 6, <i>σ</i> = 0.1, 0.3, 0.8). by Xi Chen (35903)

Subjects:

Species-level changes in biomass due to large mammalian herbivore exclusion. by Arjun B. Potter (6445646)

Table_2_Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.pdf by Tianqi Xu (9574329)

“…Background<p>Anaplastic diffuse large B-cell lymphoma(A-DLBCL) is a rare morphological subtype characterized by the presence of polygonal, bizarre-shaped tumor cells. …”

Table_1_Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.pdf by Tianqi Xu (9574329)

“…Background<p>Anaplastic diffuse large B-cell lymphoma(A-DLBCL) is a rare morphological subtype characterized by the presence of polygonal, bizarre-shaped tumor cells. …”

For a random opinion vector y(0), on ER models with <i>n</i> = 100 and <i>ρ</i> ∈ (0,1]. by Xi Chen (35903)

Subjects:

K2 increases intracellular killing of <i>K</i>. <i>pneumoniae</i> by <i>kil1</i> KO and <i>kil2</i> KO cells. by Estelle Ifrid (10076719)

Data_Sheet_1_Application of a nomogram model for the prediction of 90-day poor outcomes following mechanical thrombectomy in patients with acute anterior circulation large-vessel o... by Xia Li (14984)

“…Moreover, five variables, namely, age (odds ratio [OR]: 1.049, 95% CI [1.016–1.083]; p = 0.003), glucose level (OR: 1.163, 95% CI [1.038–1.303]; p = 0.009), baseline National Institute of Health Stroke Scale (NIHSS) score (OR: 1.066, 95% CI [0.995–1.142]; p = 0.069), unsuccessful recanalization (defined as a TICI grade of 0 to 2a) (OR: 3.730, 95% CI [1.688–8.245]; p = 0.001), and early neurological deterioration (END, defined as an increase of ≥4 points between the baseline NIHSS score and the NIHSS score at 24 h after MT) (OR: 3.383, 95% CI [1.411–8.106]; p = 0.006), were included in the nomogram to predict the potential risk of poor outcomes at 90 days following MT in LVO patients, with a C-index of 0.763 (0.693–0.832) in the training set and 0.804 (0.719–0.889) in the validation set.…”

Data_Sheet_1_Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.docx by Chengliang Yin (7545749)

“…However, the correlation between MMP14 expression, prognosis, and immune cell infiltration in diffuse large B-cell lymphoma (DLBCL) remains unclear.</p>Methods<p>We investigated the influence of MMP14 on clinical prognosis using data obtained from three Gene Expression Omnibus (GEO) database sets (GSE98588, GSE10846, and GSE4475). …”

Data_Sheet_1_Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.docx by Chengliang Yin (7545749)

“…However, the correlation between MMP14 expression, prognosis, and immune cell infiltration in diffuse large B-cell lymphoma (DLBCL) remains unclear.</p>Methods<p>We investigated the influence of MMP14 on clinical prognosis using data obtained from three Gene Expression Omnibus (GEO) database sets (GSE98588, GSE10846, and GSE4475). …”

For a random opinion vector y(0) with mean −0.0395, on 1,000 ER models with <i>n</i> = 100 and <i>ρ</i> = 0.4. by Xi Chen (35903)

Subjects:

Image_1_c-Rel Is the Pivotal NF-κB Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study.jpeg by Nathalie Faumont (7137200)

Supplementary Material for: Dysregulated MDR1 by PRDM1/Blimp1 Is Involved in the Doxorubicin Resistance of Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma by Qing K. (11765465)

“…In OCI-Ly3/DOX cells, NF-κB activity and PRDM1 expression decreased with an increase in drug-resistant index, whereas <i>MDR1</i> expression increased with enhanced drug resistance. …”